Long-Acting Injectables Patient Advisory Committee

Quick links

Committee Members • Committee Meetings • Committee Policy Assets • Committee Resources • Disclosures

Committee Members

ADAP Advocacy is currently recruiting patients and public health stakeholders to serve on its Long-Acting Injectables Patient Advisory Committee.

Download Member Directory

Download Member Directory

Committee Meetings

April 28, 2025

Meeting Agenda 04.28.25
Meeting Minutes 04.28.25
Meeting Video Archive 04.28.25
(Enter "Password2025")

BACK TO TOP

Committee Policy Assets

AIDS Drug Assistance Programs

BACK TO TOP

Committee Resources

U.S. Food & Drug Administration (FDA)

FDA Approves Sunlenca for Adults With Resistant HIV (December 2022)*
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention (December 2021)
FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection (January 2021)
FDA approves new HIV treatment for patients who have limited treatment options (March 2018)
FDA Approves Egrifta to Treat Lipodystrophy in HIV Patients (November 2010)

* Press statement no longer available on FDA's website

HIV+Hep Policy Institute

Memorandum on the Updated HIV Incidence Assumptions for the PrEP Cost Calculator

O’Neill Institute for National and Global Health Law at Georgetown University

Addressing Policy Barriers to PrEP Uptake and Planning for Long-Acting Agents

Positively Aware Magazine

Guide to Long-Acting Injectables for HIV (August 2024)
Attitudes and Access: Survey Results on Long-Acting Injectables for HIV (June 2024)

BACK TO TOP

Disclosures

This project is funded by the following corporate entities:
Gilead Sciences, Merck, and ViiV Healthcare.

BACK TO TOP